Invesco Nasdaq Biotechnology ETF closed at $35.28 on Sep 28, up 0.80%, 4.2% below its 52-week closing high. Volume of 27.1K shares was 0.96× its 20-day average (close to normal).
Split-adjusted performance: -3.2% over one month, +27.9% over six months, +50.4% over one year.
In the quarter ended Jun 30, 2026, revenue was $1.83B, up 20.5% from a year earlier, with a net margin of 18.9%.
Short interest was 57.5K shares at the Sep 15 settlement, down 18.1% from the prior report (2.5 days to cover).